Regulatory

Regulatory  ·  Weekly Digest - 20 December to 26 December 2025
Enhertu granted breakthrough therapy designation in the US as post-neoadjuvant therapy for patients with HER2-positive early breast cancer

Weekly Digest – December 2025 Weekly Digest – December 2025 22 December 2025: Enhertu granted breakthrough therapy designation in the US as post-neoadjuvant therapy for patients with HER2-positive early breast cancer AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has received its tenth FDA Breakthrough […]

by Sandhya Ramalingam

Continue Reading
Regulatory  ·  Weekly Digest - 20 December to 26 December 2025
PeptiDream announces FDA clearance of IND applications for Phase 1 clinical trials of 225Ac-PD-32766 and 64Cu-PD-32766 in patients with kidney cancer

Weekly Digest – December 2025 Weekly Digest – December 2025 22 December 2025: PeptiDream announces FDA clearance of IND applications for Phase 1 clinical trials of 225Ac-PD-32766 and 64Cu-PD-32766 in patients with kidney Cancer PeptiDream received U.S. Food and Drug […]

by Sandhya Ramalingam

Continue Reading